Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Endocrinology, Diabetes & Metabolism|January 11, 2020
Circadian-timed quick-release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitusBindu Chamarthi, Aaron Vinik, Michael Ezrokhi, et al.
Nature Clinical Practice. Endocrinology & Metabolism|August 26, 2006
Diabetic neuropathies: clinical manifestations and current treatment optionsAaron Vinik, Jagdeesh Ullal, Henri K Parson, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 14, 2017
SARCOPENIA: AN ENDOCRINE DISORDER?Alexis McKee, John E Morley, Alvin M Matsumoto, et al.
Frontiers in Endocrinology|June 4, 2019
Countering the Modern Metabolic Disease Rampage With Ancestral Endocannabinoid System AlignmentIan Pepper, Aaron Vinik, Frank Lattanzio, et al.
Pancreas|September 23, 2009
Pdx-1 regulation of the INGAP promoter involves sequestration of NeuroD into a non-DNA-binding complexDavid A Taylor-Fishwick, Wenjing Shi, Laura Hughes, et al.
Journal of Clinical Medicine|October 27, 2022
Case Report with Systematic Literature Review on Vascular Complications of BCG Intravesical Therapy for Bladder CancerBrianna King, Dhanveer Singh, Animesh Rathore, et al.
BMJ Case Reports|July 5, 2012
Chronic acetaminophen ingestion resulting in severe anion gap metabolic acidosis secondary to 5-oxoproline accumulation: an under diagnosed phenomenonL Morgan Nordstrom O'Brien, Michael Hooper, Mark Flemmer, et al.
Pain Medicine (Malden, Mass.)|April 4, 2017
Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept StudyDomenico Merante, Julio Rosenstock, Uma Sharma, et al.
Diabetes Care|September 19, 2014
Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 studyAaron Vinik, Julio Rosenstock, Uma Sharma, et al.
BMJ Open Diabetes Research & Care|May 23, 2019
Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of worldGeorge Dailey, Harpreet S Bajaj, Terry Dex, et al.
Pageof 5